Effect of zinc(II) ions on the expression of pro- and anti-apoptotic factors in high-grade prostate carcinoma cells

Sztalmachova,Marketa; Hlavna,Marian; Gumulec,Jaromir; Holubova,Monika; Babula,Petr; Balvan,Jan; Sochor,Jiri; Tanhauserova,Veronika; Raudenska,Martina; Krizkova,Sona; Adam,Vojtech; Eckschlager,Tomas; Kizek,Rene; Masarik,Michal

doi:10.3892/or.2012.1897

Effect of zinc(II) ions on the expression of pro- and anti-apoptotic factors in high-grade prostate carcinoma cells

Authors:
- Marketa Sztalmachova
- Marian Hlavna
- Jaromir Gumulec
- Monika Holubova
- Petr Babula
- Jan Balvan
- Jiri Sochor
- Veronika Tanhauserova
- Martina Raudenska
- Sona Krizkova
- Vojtech Adam
- Tomas Eckschlager
- Rene Kizek
- Michal Masarik
View Affiliations

Affiliations: Department of Pathological Physiology, Faculty of Medicine, Masaryk University, CZ-625 00 Brno, Czech Republic, Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, CZ-612 42 Brno, Czech Republic, Department of Chemistry and Biochemistry, Mendel University in Brno, CZ-613 00 Brno, Czech Republic, Department of Pathological Physiology, Faculty of Medicine, Masaryk University/Kamenice 5, CZ-625 00 Brno, Czech Republic, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, CZ-150 06 Prague 5, Czech Republic
Published online on: July 3, 2012 https://doi.org/10.3892/or.2012.1897
Pages: 806-814

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several typical characteristics of prostate tissue have been identified including the ability to accumulate zinc(II). However, this feature of prostate cells is lost during carcinogenesis and, thus, prostate cells are unable to accumulate zinc(II) ions in high levels. Therefore, we can expect that zinc(II) ions can significantly contribute to the progression of tumour disease and to the ability of prostate cell lines to metastasize. In this study, we aimed our attention on determining the expression of Bcl-2, c-Fos, c-Jun, Ki-67, NF-κB and p53 genes in two prostate cell lines, as the 22Rv1 cell line, a model of aggressive partially androgen-sensitive prostate cancer and the PNT1A cell line, a normal prostate cell line model. Moreover, we were interested in the mechanisms through which exposure of these cell lines to zinc(II) ions could influence expression of the above-mentioned genes. We found that zinc(II) ions caused elevated expression of Ki-67, a marker of proliferation, extremely low expression of p53, high expression of Bcl-2 and no changes in the expression of p53. Our experimental data show different effect of zinc(II) ions on expression of the above-mentioned regulatory genes, which may give us more information on their impact on cancer development and progression with possible using for cancer therapy.

View Figures

View References

1	Bray F, Lortet-Tieulent J, Ferlay J, Forman D and Auvinen A: Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 46:3040–3052. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ghoneum M and Gollapudi S: Susceptibility of the human LNCaP prostate cancer cells to the apoptotic effect of marina crystal minerals (MCM) in vitro. Oncol Rep. 22:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
3	Zaichick VY, Sviridova TV and Zaichick SV: Zinc in human prostate gland: normal, hyperplastic and cancerous. J Radioanal Nucl Chem. 217:157–161. 1997. View Article : Google Scholar
4	Costello LC and Franklin RB: Zinc is decreased in prostate cancer: an established relationship of prostate cancer! J Biol Inorg Chem. 16:3–8. 2011.
5	Krizkova S, Blahova P, Nakielna J, et al: Comparison of metallothionein detection by using of Brdicka reaction and enzyme-linked immunosorbent assay employing chicken yolk antibodies. Electroanalysis. 21:2575–2583. 2009. View Article : Google Scholar
6	Krizkova S, Ryvolova M, Gumulec J, et al: Electrophoretic fingerprint metallothionein analysis as a potential prostate cancer biomarker. Electrophoresis. 32:1952–1961. 2011. View Article : Google Scholar : PubMed/NCBI
7	Krizkova S, Masarik M, Eckschlager T, Adam V and Kizek R: Effects of redox conditions and zinc(II) ions on metallothionein aggregation revealed by chip capillary electrophoresis. J Chromatogr A. 1217:7966–7971. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bataineh ZM, Hani IHB and Al-Alami JR: Zinc in normal and pathological human prostate gland. Saudi Med J. 23:218–220. 2002.PubMed/NCBI
9	Cory S, Huang DCS and Adams JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 22:8590–8607. 2003. View Article : Google Scholar : PubMed/NCBI
10	Bruckheimer EM, Cho S, Brisbay S, et al: The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene. 19:2404–2412. 2000. View Article : Google Scholar : PubMed/NCBI
11	Gastman BR: Apoptosis and its clinical impact. Head Neck-J Sci Spec Head Neck. 23:409–425. 2001. View Article : Google Scholar : PubMed/NCBI
12	Gross A, McDonnell JM and Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
13	Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD and Rosser CJ: Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther. 6:101–111. 2007. View Article : Google Scholar : PubMed/NCBI
14	Xu L, Yang DJ, Wang SM, et al: (-)-gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther. 4:197–205. 2005.PubMed/NCBI
15	Nomura T, Yamasaki M, Nomura Y and Mimata H: Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep. 14:993–997. 2005.PubMed/NCBI
16	Concato J, Jain D, Uchio E, Risch H, Li WW and Wells CK: Molecular markers and death from prostate cancer. Ann Intern Med. 150:U595–U596. 2009. View Article : Google Scholar
17	Dachille G, Cai T, Ludovico GM, et al: Prognostic role of cell apoptotic rate in prostate cancer: outcome of a long-time follow-up study. Oncol Rep. 19:541–545. 2008.PubMed/NCBI
18	Catz SD and Johnson JL: Bcl-2 in prostate cancer: a minireview. Apoptosis. 8:29–37. 2003. View Article : Google Scholar : PubMed/NCBI
19	Masarik M, Gumulec J, Sztalmachova M, et al: Isolation of metallothionein from cells derived from aggressive form of high-grade prostate carcinoma using paramagnetic antibody-modified microbeads off-line coupled with electrochemical and electrophoretic analysis. Electrophoresis. 32:3576–3588. 2011. View Article : Google Scholar
20	Babula P, Kohoutkova V, Opatrilova R, Dankova I, Masarik M and Kizek R: Pharmaceutical importance of zinc and metallothionein in cell signalling. Chim Oggi-Chem Today. 28:18–21. 2010.
21	Krizkova S, Fabrik I, Adam V, Hrabeta J, Eckschlager T and Kizek R: Metallothionein - a promising tool for cancer diagnostics. Bratisl Med J-Bratisl Lek Listy. 110:93–97. 2009.PubMed/NCBI
22	Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci. 10:360–375. 2009. View Article : Google Scholar : PubMed/NCBI
23	Adam V, Fabrik I, Eckschlager T, Stiborova M, Trnkova L and Kizek R: Vertebrate metallothioneins as target molecules for analytical techniques. TRAC-Trends Anal Chem. 29:409–418. 2010. View Article : Google Scholar
24	Ryvolova M, Adam V and Kizek R: Analysis of metallothionein by capillary electrophoresis (review). J Chromatogr A. 1226:31–42. 2012. View Article : Google Scholar
25	Ryvolova M, Krizkova S, Adam V, et al: Analytical methods for metallothionein detection. Curr Anal Chem. 7:243–261. 2011.
26	Costello LC, Liu YY, Franklin RB and Kennedy MC: Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells. J Biol Chem. 272:28875–28881. 1997. View Article : Google Scholar : PubMed/NCBI
27	Beyersmann D and Haase H: Functions of zinc in signaling, proliferation and differentiation of mammalian cells. Biometals. 14:331–341. 2001. View Article : Google Scholar : PubMed/NCBI
28	Baranano DE, Ferris CD and Snyder SH: Atypical neural messengers. Trends Neurosci. 24:99–106. 2001. View Article : Google Scholar : PubMed/NCBI
29	Hogstrand C, Kille P, Nicholson RI and Taylor KM: Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation. Trends Mol Med. 15:101–111. 2009. View Article : Google Scholar : PubMed/NCBI
30	Costello LC and Franklin RB: The intermediary metabolism of the prostate: A key to understanding the pathogenesis and progression of prostate malignancy. Oncology. 59:269–282. 2000. View Article : Google Scholar : PubMed/NCBI
31	Gumulec J, Masarik M, Krizkova S, et al: Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma. Curr Med Chem. 18:5041–5051. 2011. View Article : Google Scholar : PubMed/NCBI
32	Scott SL, Higdon R, Beckett L, et al: Bcl-2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm. 17:647–656. 2002. View Article : Google Scholar : PubMed/NCBI
33	Hess J, Angel P and Schorpp-Kistner M: AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 117:5965–5973. 2004. View Article : Google Scholar : PubMed/NCBI
34	Ameyar M, Wisniewska M and Weitzman JB: A role for AP-1 in apoptosis: the case for and against. Biochimie. 85:747–752. 2003. View Article : Google Scholar : PubMed/NCBI
35	Leppa S and Bohmann D: Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene. 18:6158–6162. 1999. View Article : Google Scholar : PubMed/NCBI
36	Wisdom R, Johnson RS and Moore C: c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 18:188–197. 1999. View Article : Google Scholar : PubMed/NCBI
37	Charital YM, van Haasteren G, Massiha A, Schlegel W and Fujita T: A functional NF-kappaB enhancer element in the first intron contributes to the control of c-fos transcription. Gene. 430:116–122. 2009. View Article : Google Scholar : PubMed/NCBI
38	Huang L, Kirschke CP and Zhang Y: Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell Int. 6:1–10. 2006. View Article : Google Scholar : PubMed/NCBI
39	Golovine K, Uzzo RG, Makhov P, Crispen PL, Kunkle D and Kolenko VM: Depletion of intracellular zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappa B-dependent pathway. Prostate. 68:1443–1449. 2008. View Article : Google Scholar : PubMed/NCBI
40	Radhakrishnan SK and Kamalakaran S: Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim Biophys Acta. 1766:53–62. 2006.PubMed/NCBI
41	Bohuslav J, Chen LF, Kwon H, Mu YJ and Greene WC: p53 induces NF-kappa B activation by an I kappa B kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem. 279:26115–26125. 2004. View Article : Google Scholar : PubMed/NCBI
42	Webster GA and Perkins ND: Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol. 19:3485–3495. 1999.PubMed/NCBI
43	Chowdhury R, Chowdhury S, Roychoudhury P, Mandal C and Chaudhuri K: Arsenic induced apoptosis in malignant melanoma cells is enhanced by menadione through ROS generation, p38 signaling and p53 activation. Apoptosis. 14:108–123. 2009. View Article : Google Scholar : PubMed/NCBI
44	Li ZS, Shi KJ, Guan LY, et al: ROS leads to MnSOD upregulation through ERK2 translocation and p53 activation in selenite-induced apoptosis of NB4 cells. FEBS Lett. 584:2291–2297. 2010. View Article : Google Scholar : PubMed/NCBI
45	Bragado P, Armesilla A, Silva A and Porras A: Apoptosis by cisplatin requires p53 mediated p38 alpha MAPK activation through ROS generation. Apoptosis. 12:1733–1742. 2007. View Article : Google Scholar : PubMed/NCBI
46	Bullwinkel J, Baron-Luhr B, Ludemann A, Wohlenberg C, Gerdes J and Scholzen T: Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol. 206:624–635. 2006. View Article : Google Scholar : PubMed/NCBI
47	Rahmanzadeh R, Huttmann G, Gerdes J and Scholzen T: Chromophore-assisted light inactivation of pKi-67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif. 40:422–430. 2007. View Article : Google Scholar : PubMed/NCBI
48	Nariculam J, Freeman A, Bott S, et al: Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of Bcl-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl. 11:109–118. 2009.
49	Mitra AV, Jameson C, Barbachano Y, et al: Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers. Oncol Rep. 23:299–305. 2010.PubMed/NCBI
50	Khatami A, Hugosson J, Wang WZ and Damber JE: Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand J Urol Nephrol. 43:12–18. 2009. View Article : Google Scholar
51	Jhavar S, Bartlett J, Kovacs G, et al: Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis. 12:143–147. 2009. View Article : Google Scholar : PubMed/NCBI
52	Li RL, Heydon K, Hammond ME, et al: Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 10:4118–4124. 2004. View Article : Google Scholar